As Delta takes con­trol, US re­sumes use of Lil­ly's Covid-19 mAb com­bo na­tion­wide

A lit­tle more than two months af­ter the US halt­ed all ship­ments of Eli Lil­ly’s mon­o­clon­al an­ti­body com­bo for the treat­ment of Covid-19 on a na­tion­al ba­sis, the FDA has de­cid­ed that the use of the drug can re­sume across the coun­try.

“Based on the most cur­rent­ly avail­able da­ta, bam­lanivimab and ete­se­vimab are now au­tho­rized in all U.S. states, ter­ri­to­ries, and ju­ris­dic­tions,” the FDA said yes­ter­day, not­ing in a fact sheet that the com­bo re­tained ac­tiv­i­ty against the Delta vari­ant. The com­bo had pre­vi­ous­ly been pulled be­cause it strug­gled to work against the Be­ta and Gam­ma vari­ants, which are now no longer preva­lent in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.